Seres Therapeutics, Inc

(NASDAQ:MCRB)

Latest On Seres Therapeutics, Inc (MCRB):

Date/Time Type Description Signal Details
2023-05-30 17:25 ESTNewsSeres receives $125M milestone payment for FDA Approval of Vowst for C. difficile InfectionN/A
2023-05-23 14:58 ESTNewsSeres Q1 Earnings: Major News For InvestorsN/A
2023-05-23 00:11 ESTNewsSeres Therapeutics: Still Work To Do Before Realizing Its PotentialN/A
2023-05-09 15:43 ESTNewsSeres Therapeutics GAAP EPS of -$0.57 misses by $0.02N/A
2023-05-09 15:42 ESTNewsSeres Therapeutics, Inc. (MCRB) Q1 2023 Earnings Call TranscriptN/A
2023-05-09 01:59 ESTNewsSeres Therapeutics Q1 2023 Earnings PreviewN/A
2023-05-03 13:01 ESTNewsSeres Gets FDA Approval And The Share Price Goes Down!N/A
2023-04-27 07:33 ESTNewsSeres adds 11% on FDA nod microbiome therapyN/A
2023-04-22 20:35 ESTNewsStocks To Watch: Microsoft, Amazon And Coca-Cola Headline Huge Earnings WeekN/A
2023-04-17 23:40 ESTNewsSeres hits four-month high ahead of FDA decision on lead assetN/A
2023-04-06 00:47 ESTNewsSeres Therapeutics: Binary Catalyst UnlockingN/A
2023-03-07 21:52 ESTNewsSeres Therapeutics GAAP EPS of -$2.31 misses by $0.15, revenue of $7.13M misses by $6.62MN/A
2023-03-07 21:52 ESTNewsSeres Therapeutics falls 9% on full-year earnings missN/A
2023-03-07 21:51 ESTNewsSeres Therapeutics, Inc. (MCRB) Q4 2022 Earnings Call TranscriptN/A
2023-03-06 16:34 ESTNewsSeres Therapeutics FY 2022 Earnings PreviewN/A
2023-02-06 20:00 ESTNewsSeres Therapeutics: FDA Approval Straight AheadN/A
2023-02-05 18:02 ESTNewsThe Clock Is Ticking For Seres Therapeutics: I'm Not AfraidN/A
2022-12-09 21:16 ESTNewsSeres Therapeutics (MCRB) Investor Presentation - SlideshowN/A
2022-11-10 19:57 ESTNewsSeres Gets Closer To Good TimesN/A
2022-11-02 20:10 ESTNewsSeres Therapeutics GAAP EPS of -$0.49 misses by $0.02, revenue of $3.44M misses by $3.57MN/A
2022-11-02 20:10 ESTNewsSeres stock sinks as Q3 plunges in lossN/A
2022-11-02 20:10 ESTNewsSeres Therapeutics, Inc. (MCRB) Q3 2022 Earnings Call TranscriptN/A
2022-10-26 19:58 ESTNewsSeres microbiome therapy for bacterial infection gets FDA priority reviewN/A
2022-09-07 21:20 ESTNewsSeres completes regulatory submissions seeking FDA nod for lead assetN/A
2022-08-20 04:43 ESTNewsSeres Therapeutics: What The Market Is MissingN/A
2022-08-03 23:17 ESTNewsSeres rises 16% as co expects to file BLA for C. difficile infection treatment in coming weeksN/A
2022-08-03 23:17 ESTNewsSeres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-03 08:18 ESTNewsSeres Therapeutics GAAP EPS of -$0.70 misses by $0.10, revenue of $1.22MN/A
2022-07-13 04:02 ESTNewsSeres Therapeutics: The Good And The ChallengingN/A
2022-06-30 13:41 ESTNewsSeres Therapeutics stock slips on $100M stock offeringN/A
2022-06-11 04:19 ESTNewsSeres Therapeutics: The Pipeline Is The ProblemN/A
2022-06-09 19:45 ESTNewsSeres Therapeutics: As Biotech Fades, The Case For The Company's Investment StrengthensN/A
2022-06-07 14:32 ESTNewsSeres Therapeutics posts additional safety data for lead candidateN/A
2022-05-05 06:07 ESTNewsSeres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-04 09:15 ESTNewsSeres Therapeutics GAAP EPS of -$0.61 misses by $0.09, revenue of $1.49MN/A
2022-05-03 17:34 ESTNewsSeres Therapeutics Q1 2022 Earnings PreviewN/A
2022-03-06 11:37 ESTNewsSeres Therapeutics Is Playing A Long GameN/A
2022-03-02 20:11 ESTNewsSeres Therapeutics (MCRB) Presents At Chardan's Microbiome and Metagenomics Summit - SlideshowN/A
2022-03-02 03:42 ESTNewsSeres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q4 2021 Results - Earnings Call TranscriptN/A
2022-03-01 09:35 ESTNewsSeres Therapeutics GAAP EPS of -$0.72 misses by $0.10, revenue of $144.92M misses by $4.9MN/A
2022-01-20 06:51 ESTNewsSeres late-stage data on microbiome therapy shows efficacy against C. difficile infectionN/A
2021-12-01 04:59 ESTNewsSeres Therapeutics at a four-month high after update on study for microbiome drugN/A
2021-11-11 09:21 ESTNewsSeres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q3 2021 Results - Earnings Call TranscriptN/A
2021-11-11 09:21 ESTNewsSeres Therapeutics shares surge 30% after Q3 earnings beatN/A
2021-11-10 11:48 ESTNewsSeres Therapeutics EPS beats by $0.75, beats on revenueN/A
2021-11-10 11:47 ESTNewsSeres Therapeutics and Bacthera ink collaboration agreementN/A
2021-11-10 11:47 ESTNewsRed Light For Seres Therapeutics, But Not A Stop Light For MeN/A
2021-11-09 12:47 ESTNewsSeres Therapeutics Q3 2021 Earnings PreviewN/A
2021-10-04 08:40 ESTNewsSeres Therapeutics reports data from late-stage SER-109 study at IDWeek2021N/A
2021-10-04 08:38 ESTNewsSeres Therapeutics Molecular Data On SER-109 Looks GoodN/A

About Seres Therapeutics, Inc (MCRB):

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-287 that is in Phase IIb clinical trial to treat ulcerative colitis; SER-401, which is in Phase Ib clinical trial for use with checkpoint inhibitors in patients with metastatic melanoma; and SER-301 that is in the Phase 1b clinical trial for the treatment of inflammatory bowel disease. In addition, the company engages in the development of SER-262 to treat an initial recurrence of CDI; and SER-155, a cultivated bacteria microbiome drug designed to prevent mortality due to gastrointestinal infections, bacteremia, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

See Advanced Chart

General

  • Name Seres Therapeutics, Inc
  • Symbol MCRB
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 155
  • Fiscal Year EndDecember
  • IPO Date2015-06-26
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.serestherapeutics.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 48.74
  • Price/Book (Most Recent Quarter) 10.63
  • Enterprise Value Revenue 49.52
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$1.42
  • Next Year EPS Estimate -$1.30
  • Next Quarter EPS Estimate -$0.31
  • Profit Margin -268%
  • Operating Margin -265%
  • Return on Assets -23%
  • Return on Equity -141%
  • Revenue 33.22 million
  • Earnings Per Share -$1.87
  • Revenue Per Share $0.42
  • Gross Profit -57355000
  • Quarterly Earnings Growth 130.4%
View More

Highlights

  • Market Capitalization 1.9 billion
  • EBITDA -69997000
  • PE Ratio -0.75
  • PEG Ratio -0.11
  • Analyst Target Price $37.57
  • Book Value Per Share $1.91
View More

Share Statistics

  • Shares Outstanding 91.55 million
  • Shares Float 68.32 million
  • % Held by Insiders 926%
  • % Held by Institutions 81.2%
  • Shares Short 6.56 million
  • Shares Short Prior Month 5.96 million
  • Short Ratio 7.17
  • Short % of Float 12%
  • Short % of Shares Outstanding 7%
View More

Technicals

  • Beta 3.96
  • 52 Week High $38.5
  • 52 Week Low $3.01
  • 50 Day Moving Average 22.75
  • 200 Day Moving Average 26.66
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Seres Therapeutics, Inc (MCRB) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Seres Therapeutics, Inc (MCRB) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-02$17.56 million-$0.19-$0.2832.14%
2020-09-302020-11-09$N/A-$0.36-$0.26-40.46%
2020-06-302020-07-28$6.05 million-$0.28-$0.26-8.28%
2020-03-312020-05-07$8.19 million-$0.28-$0.26-7.69%
2019-12-312020-03-02$7.62 million-$0.25-$0.2810.17%
2019-09-302019-11-05$7.03 million-$0.23-$0.2818.35%
2019-06-302019-08-06$12.53 million-$0.24-$0.4850.39%
2019-03-312019-05-02$7.32 million-$0.59-$0.44-33.57%
2018-12-312019-03-06$10.63 million-$0.52-$0.6924.91%
2018-09-302018-11-08$9.06 million-$0.54-$0.6314.83%
2018-06-302018-08-02$4.61 million-$0.68-$0.725.78%
2018-03-312018-05-09$3.97 million-$0.69-$0.769.69%
2017-12-312018-03-08$3.06 million-$0.72-$0.754.18%
2017-09-302017-11-08$23.02 million-$0.17-$0.5669.64%
2017-06-302017-08-03$3.01 million-$0.69-$0.64-8.15%
2017-03-312017-05-04$3.02 million-$0.63-$0.664.79%
2016-12-312017-03-16$3.04 million-$0.64-$0.7514.29%
2016-09-302016-11-10$13.02 million-$0.46-$0.5617.37%
2016-06-302016-08-11$3 million-$0.70-$0.45-55.56%
2016-03-312016-05-16$2.71 million-$0.50-$0.48-4.89%
2015-12-312016-02-25$N/A-$0.41-$0.433.53%
2015-09-302015-11-10$N/A-$0.38-$0.32-18.75%
2015-06-302015-07-01$N/A-$1.45-$0.30-383.33%

Seres Therapeutics, Inc (MCRB) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Seres Therapeutics, Inc (MCRB) Chart:

Seres Therapeutics, Inc (MCRB) News:

Below you will find a list of latest news for Seres Therapeutics, Inc (MCRB) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Seres Therapeutics, Inc (MCRB) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2026-03-202.50CALL0 0408.7TRUE00
2026-03-2050CALL0 0183.86TRUE00
2026-03-207.50CALL0 0180.34TRUE00
2026-03-20100.85CALL0 14284.94FALSE00
2026-03-2012.50.75CALL0 1207.88FALSE00
2026-03-20150.25CALL0 16546.15FALSE00
2026-03-2017.50.43CALL0 2434.13FALSE00
2026-03-20201CALL0 3466.8FALSE00
2026-03-2022.50.1CALL0 20631.17FALSE00
2026-03-20250CALL0 0690.83FALSE00
2026-03-20300CALL0 0733.59FALSE00
2026-03-202.50PUT0 00FALSE00
2026-03-2050.05PUT0 1826.55FALSE00
2026-03-207.50.65PUT0 16323.69FALSE00
2026-03-20102.22PUT0 3466.91TRUE00
2026-03-2012.51.55PUT0 2134.71TRUE00
2026-03-20152.8PUT0 2143.15TRUE00
2026-03-2017.54.7PUT0 10TRUE00
2026-03-20207.1PUT0 1206.95TRUE00
2026-03-2022.59.4PUT0 20TRUE00
2026-03-20250PUT0 00TRUE00
2026-03-203015.8PUT0 20TRUE00
2026-04-172.50CALL0 0168.46TRUE00
2026-04-1750CALL0 0118.94TRUE00
2026-04-177.51.95CALL0 2134.28TRUE00
2026-04-17101.65CALL0 18135.01FALSE00
2026-04-1712.50.7CALL12 22135.3FALSE0.70
2026-04-17150.4CALL1 58139.07FALSE0.40
2026-04-1717.52.4CALL0 140278.27FALSE00
2026-04-17200.5CALL0 229376.17FALSE00
2026-04-1722.51.55CALL0 96391.98FALSE00
2026-04-17251.38CALL0 215400.89FALSE00
2026-04-17300.2CALL0 1087226.07FALSE00
2026-04-17351.4CALL0 1327.32FALSE00
2026-04-17400.05CALL1 220194.97FALSE0.050
2026-04-172.50PUT0 01061.93FALSE00
2026-04-1750PUT0 0483.11FALSE00
2026-04-177.50.85PUT0 10190.72FALSE00
2026-04-17102.3PUT0 4107.77TRUE00
2026-04-1712.54.1PUT1 158141.93TRUE4.10
2026-04-17156.4PUT0 85136.36TRUE00
2026-04-1717.55.8PUT0 4174.11TRUE00
2026-04-172011.81PUT0 6195.68TRUE00
2026-04-1722.510PUT0 5193.83TRUE00
2026-04-172511.8PUT0 5201.22TRUE00
2026-04-173016.5PUT0 23207.26TRUE00
2026-04-173521.7PUT0 1214.64TRUE00
2026-04-174025PUT0 10TRUE00
2026-07-172.50CALL0 00TRUE00
2026-07-1750CALL0 0104.47TRUE00
2026-07-177.50CALL0 0117.94TRUE00
2026-07-17102.2CALL1 2114.26FALSE2.20
2026-07-1712.51.65CALL1 2119.22FALSE1.650
2026-07-17151.05CALL0 53111.92FALSE00
2026-07-1717.50.85CALL0 17216.2FALSE00
2026-07-17201.92CALL0 36222.5FALSE00
2026-07-1722.53.2CALL0 126231.32FALSE00
2026-07-17252.5CALL0 525238.61FALSE00
2026-07-17302.22CALL0 116249.87FALSE00
2026-07-17351.95CALL0 1260.33FALSE00
2026-07-17400CALL0 0268.68FALSE00
2026-07-172.50PUT0 0653.13FALSE00
2026-07-1750.8PUT0 10207.65FALSE00
2026-07-177.51.52PUT0 14117.78FALSE00
2026-07-17103.6PUT0 9124.7TRUE00
2026-07-1712.55.5PUT0 7113.13TRUE00
2026-07-17155.7PUT0 7135.09TRUE00
2026-07-1717.59.9PUT0 2140.11TRUE00
2026-07-17209.7PUT0 1148.92TRUE00
2026-07-1722.50PUT0 1155.38TRUE00
2026-07-17250PUT0 0160.03TRUE00
2026-07-173017.6PUT0 1165.27TRUE00
2026-07-17350PUT0 0172.55TRUE00
2026-07-17400PUT0 0173.54TRUE00
2026-10-162.50CALL0 078.31TRUE00
2026-10-1653.9CALL0 1112.79TRUE00
2026-10-167.52.65CALL0 1119.22TRUE00
2026-10-16100CALL0 0114.51FALSE00
2026-10-1612.50CALL0 199.68FALSE00
2026-10-16150CALL0 093.74FALSE00
2026-10-1617.50CALL0 0133.93FALSE00
2026-10-162.50PUT0 0486.11FALSE00
2026-10-1650PUT0 0269.54FALSE00
2026-10-167.50PUT0 6127.27FALSE00
2026-10-16104PUT1 1128.56TRUE40
2026-10-1612.55.9PUT1 2130TRUE5.90
2026-10-16158.1PUT1 3136.76TRUE00
2026-10-1617.510PUT0 1118.41TRUE00
2027-01-150.50CALL0 6740TRUE00
2027-01-1510CALL0 1030TRUE00
2027-01-151.50CALL0 40TRUE00
2027-01-1520CALL0 150TRUE00
2027-01-152.50CALL0 0109.06TRUE00
2027-01-1550CALL0 0145.64TRUE00
2027-01-157.50CALL0 0100.4TRUE00
2027-01-15100CALL0 0106.1FALSE00
2027-01-1512.52.58CALL0 10105.65FALSE00
2027-01-15157.9CALL0 2109.75FALSE00
2027-01-1517.50.7CALL0 12184.58FALSE00
2027-01-15204.7CALL0 54189.55FALSE00
2027-01-1522.50CALL0 0193.33FALSE00
2027-01-152512.25CALL0 3196.21FALSE00
2027-01-15302.25CALL0 10203.2FALSE00
2027-01-15350CALL0 0211.39FALSE00
2027-01-15400CALL0 0215.16FALSE00
2027-01-150.50PUT0 20308.7FALSE00
2027-01-1510PUT0 00FALSE00
2027-01-151.50PUT0 10FALSE00
2027-01-1520PUT0 00FALSE00
2027-01-152.50PUT0 00FALSE00
2027-01-1550.95PUT0 3289.01FALSE00
2027-01-157.52.7PUT0 5203.24FALSE00
2027-01-15103PUT0 412116.52TRUE00
2027-01-1512.55.23PUT0 451113.01TRUE00
2027-01-15158.5PUT0 400102.61TRUE00
2027-01-1517.50PUT0 0108.46TRUE00
2027-01-152012.54PUT0 2112.11TRUE00
2027-01-1522.50PUT0 0112.5TRUE00
2027-01-15250PUT0 0118.02TRUE00
2027-01-15300PUT0 0126.86TRUE00
2027-01-15350PUT0 0126.01TRUE00
2027-01-15400PUT0 0132.67TRUE00

Latest MCRB Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST300$2.765
Jun 13, 2022 7:59 PM EST100$2.765
Jun 13, 2022 7:59 PM EST100$2.76
Jun 13, 2022 7:59 PM EST5$2.76
Jun 13, 2022 7:59 PM EST200$2.765

Seres Therapeutics, Inc (MCRB) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-07-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924320018111/0000899243-20-018111-index.htm
2020-03-13UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1609809/000000000020002288/0000000000-20-002288-index.htm
2019-02-08SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1609809/000021545719006834/0000215457-19-006834-index.htm
2019-07-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1609809/000021545719008320/0000215457-19-008320-index.htm
2019-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1609809/000031506619001315/0000315066-19-001315-index.htm
2019-11-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1609809/000031506619001764/0000315066-19-001764-index.htm
2020-02-07SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1609809/000031506620001189/0000315066-20-001189-index.htm
2020-09-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1609809/000031506620001720/0000315066-20-001720-index.htm
2020-02-07SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1609809/000083423720008241/0000834237-20-008241-index.htm
2018-06-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924318018511/0000899243-18-018511-index.htm
2018-06-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924318018512/0000899243-18-018512-index.htm
2018-06-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924318018513/0000899243-18-018513-index.htm
2018-06-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924318018515/0000899243-18-018515-index.htm
2018-06-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924318018518/0000899243-18-018518-index.htm
2018-06-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924318018520/0000899243-18-018520-index.htm
2018-06-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924318018521/0000899243-18-018521-index.htm
2018-06-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924318018522/0000899243-18-018522-index.htm
2018-06-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924318018742/0000899243-18-018742-index.htm
2018-07-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924318019711/0000899243-18-019711-index.htm
2018-07-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924318019814/0000899243-18-019814-index.htm
2018-07-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924318020074/0000899243-18-020074-index.htm
2018-09-043Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924318023727/0000899243-18-023727-index.htm
2018-09-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924318023729/0000899243-18-023729-index.htm
2018-09-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924318023938/0000899243-18-023938-index.htm
2018-09-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924318024194/0000899243-18-024194-index.htm
2018-09-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924318024819/0000899243-18-024819-index.htm
2018-10-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924318026790/0000899243-18-026790-index.htm
2018-10-243Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924318027398/0000899243-18-027398-index.htm
2018-10-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924318027399/0000899243-18-027399-index.htm
2018-11-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924318029310/0000899243-18-029310-index.htm
2018-12-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924318031411/0000899243-18-031411-index.htm
2019-01-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924319002136/0000899243-19-002136-index.htm
2019-01-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924319002137/0000899243-19-002137-index.htm
2019-01-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924319002138/0000899243-19-002138-index.htm
2019-01-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924319002141/0000899243-19-002141-index.htm
2019-01-294Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924319002142/0000899243-19-002142-index.htm
2019-02-113Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924319003202/0000899243-19-003202-index.htm
2019-02-153/AInitial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924319003843/0000899243-19-003843-index.htm
2019-04-243Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924319011035/0000899243-19-011035-index.htm
2019-06-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924319017010/0000899243-19-017010-index.htm
2019-06-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924319017012/0000899243-19-017012-index.htm
2019-06-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924319017013/0000899243-19-017013-index.htm
2019-06-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924319017016/0000899243-19-017016-index.htm
2019-06-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924319017018/0000899243-19-017018-index.htm
2019-06-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924319017019/0000899243-19-017019-index.htm
2019-06-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924319017029/0000899243-19-017029-index.htm
2019-06-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924319017036/0000899243-19-017036-index.htm
2019-06-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924319017038/0000899243-19-017038-index.htm
2019-06-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924319017640/0000899243-19-017640-index.htm
2019-06-283Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924319018536/0000899243-19-018536-index.htm
2019-08-063Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924319021169/0000899243-19-021169-index.htm
2019-08-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924319021170/0000899243-19-021170-index.htm
2019-11-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924319028069/0000899243-19-028069-index.htm
2020-01-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924320002210/0000899243-20-002210-index.htm
2020-01-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924320002211/0000899243-20-002211-index.htm
2020-01-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924320002212/0000899243-20-002212-index.htm
2020-01-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924320002213/0000899243-20-002213-index.htm
2020-01-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924320002418/0000899243-20-002418-index.htm
2020-01-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924320002419/0000899243-20-002419-index.htm
2020-01-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924320002420/0000899243-20-002420-index.htm
2020-01-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924320002422/0000899243-20-002422-index.htm
2020-01-314Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924320002423/0000899243-20-002423-index.htm
2020-03-233Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924320009247/0000899243-20-009247-index.htm
2020-03-234Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924320009250/0000899243-20-009250-index.htm
2020-04-073Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924320010404/0000899243-20-010404-index.htm
2020-04-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924320010407/0000899243-20-010407-index.htm
2020-04-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924320011277/0000899243-20-011277-index.htm
2020-06-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924320017347/0000899243-20-017347-index.htm
2020-06-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924320017353/0000899243-20-017353-index.htm
2020-06-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924320017354/0000899243-20-017354-index.htm
2020-06-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924320017355/0000899243-20-017355-index.htm
2020-06-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924320017356/0000899243-20-017356-index.htm
2020-06-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924320017357/0000899243-20-017357-index.htm
2020-06-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924320017361/0000899243-20-017361-index.htm
2020-06-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924320017363/0000899243-20-017363-index.htm
2020-07-013Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924320018109/0000899243-20-018109-index.htm
2020-07-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924320018111/0000899243-20-018111-index.htm
2020-10-213Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924320028908/0000899243-20-028908-index.htm
2020-10-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1609809/000089924320028909/0000899243-20-028909-index.htm
2020-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1609809/000095010320002661/0000950103-20-002661-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1609809/000110465920021149/0001104659-20-021149-index.htm
2020-10-09SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1609809/000110465920113858/0001104659-20-113858-index.htm
2019-09-06SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1609809/000114036119016287/0001140361-19-016287-index.htm
2020-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1609809/000114036120002975/0001140361-20-002975-index.htm
2020-09-08SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1609809/000114036120019924/0001140361-20-019924-index.htm
2019-02-14SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1609809/000114420419007781/0001144204-19-007781-index.htm
2018-06-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1609809/000119312518205796/0001193125-18-205796-index.htm
2018-08-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1609809/000119312518235595/0001193125-18-235595-index.htm
2018-08-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1609809/000119312518240749/0001193125-18-240749-index.htm
2018-09-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1609809/000119312518265488/0001193125-18-265488-index.htm
2018-10-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1609809/000119312518303575/0001193125-18-303575-index.htm
2018-11-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1609809/000119312518320919/0001193125-18-320919-index.htm
2018-11-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1609809/000119312518321819/0001193125-18-321819-index.htm
2018-11-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1609809/000119312518331898/0001193125-18-331898-index.htm
2019-01-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1609809/000119312519009357/0001193125-19-009357-index.htm
2019-03-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1609809/000119312519064643/0001193125-19-064643-index.htm
2019-03-06S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1609809/000119312519065218/0001193125-19-065218-index.htm
2019-03-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1609809/000119312519070257/0001193125-19-070257-index.htm
2019-04-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1609809/000119312519110877/0001193125-19-110877-index.htm
2019-04-30DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1609809/000119312519129317/0001193125-19-129317-index.htm
2019-04-30DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1609809/000119312519129353/0001193125-19-129353-index.htm
2019-05-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1609809/000119312519133801/0001193125-19-133801-index.htm
2019-06-12424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1609809/000119312519171388/0001193125-19-171388-index.htm
2019-06-14424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1609809/000119312519173661/0001193125-19-173661-index.htm
2019-06-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1609809/000119312519173673/0001193125-19-173673-index.htm
2019-06-28SC 13DGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1609809/000119312519186075/0001193125-19-186075-index.htm
2019-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1609809/000119312519213482/0001193125-19-213482-index.htm
2019-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1609809/000119312519213483/0001193125-19-213483-index.htm
2019-11-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1609809/000119312519283493/0001193125-19-283493-index.htm
2019-11-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1609809/000119312519284005/0001193125-19-284005-index.htm
2019-11-27424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1609809/000119312519301823/0001193125-19-301823-index.htm
2019-11-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1609809/000119312519301827/0001193125-19-301827-index.htm
2019-12-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1609809/000119312519314364/0001193125-19-314364-index.htm
2020-03-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1609809/000119312520057817/0001193125-20-057817-index.htm
2020-03-02S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1609809/000119312520058927/0001193125-20-058927-index.htm
2020-03-09S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1609809/000119312520067187/0001193125-20-067187-index.htm
2020-03-16CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1609809/000119312520074860/0001193125-20-074860-index.htm
2020-03-18424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1609809/000119312520077200/0001193125-20-077200-index.htm
2020-03-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1609809/000119312520077213/0001193125-20-077213-index.htm
2020-03-238-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1609809/000119312520081498/0001193125-20-081498-index.htm
2020-04-30DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1609809/000119312520128784/0001193125-20-128784-index.htm
2020-04-30DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1609809/000119312520128794/0001193125-20-128794-index.htm
2020-05-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1609809/000119312520135559/0001193125-20-135559-index.htm
2020-06-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1609809/000119312520175590/0001193125-20-175590-index.htm
2020-08-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1609809/000119312520214096/0001193125-20-214096-index.htm
2020-08-11S-3ASRAutomatic shelf registration statement of securities of well-known seasoned issuershttps://www.sec.gov/Archives/edgar/data/1609809/000119312520216465/0001193125-20-216465-index.htm
2020-08-11424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1609809/000119312520216509/0001193125-20-216509-index.htm
2020-08-13FWPFiling under Securities Act Rules 163/433 of free writing prospectuseshttps://www.sec.gov/Archives/edgar/data/1609809/000119312520217856/0001193125-20-217856-index.htm
2020-08-13FWPFiling under Securities Act Rules 163/433 of free writing prospectuseshttps://www.sec.gov/Archives/edgar/data/1609809/000119312520218233/0001193125-20-218233-index.htm
2020-08-14424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1609809/000119312520220573/0001193125-20-220573-index.htm
2020-08-14424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1609809/000119312520220574/0001193125-20-220574-index.htm
2020-08-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1609809/000119312520220584/0001193125-20-220584-index.htm
2020-08-17FWPFiling under Securities Act Rules 163/433 of free writing prospectuseshttps://www.sec.gov/Archives/edgar/data/1609809/000119312520222451/0001193125-20-222451-index.htm
2020-08-19SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1609809/000119312520224776/0001193125-20-224776-index.htm
2019-09-09SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1609809/000121465919005718/0001214659-19-005718-index.htm
2020-09-09SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1609809/000121465920007732/0001214659-20-007732-index.htm
2018-08-0210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1609809/000156459018018757/0001564590-18-018757-index.htm
2018-11-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1609809/000156459018028339/0001564590-18-028339-index.htm
2019-03-0610-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1609809/000156459019006423/0001564590-19-006423-index.htm
2019-05-0210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1609809/000156459019015070/0001564590-19-015070-index.htm
2019-08-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1609809/000156459019029069/0001564590-19-029069-index.htm
2019-11-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1609809/000156459019040255/0001564590-19-040255-index.htm
2020-03-0210-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1609809/000156459020008002/0001564590-20-008002-index.htm
2020-05-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1609809/000156459020022457/0001564590-20-022457-index.htm
2020-07-2810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1609809/000156459020033715/0001564590-20-033715-index.htm
2020-03-18EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1609809/999999999520000587/9999999995-20-000587-index.htm
2019-04-15CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1609809/999999999719002897/9999999997-19-002897-index.htm

Seres Therapeutics, Inc (MCRB) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Seres Therapeutics, Inc (MCRB). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 926%
Institutional Ownership: 8120%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2018-10-15John G. AuninsOfficerSell14,279.005.9484,800.13103,811.00https://www.sec.gov/Archives/edgar/data/1609809/000089924318026790/0000899243-18-026790-index.htm
2020-01-26John G. AuninsChief Technology Officer & EVPBuy12,500.00105,250.00https://www.sec.gov/Archives/edgar/data/1609809/000089924320002210/0000899243-20-002210-index.htm
2018-09-17John G. AuninsOfficerSell14,279.007.27103,875.44118,090.00https://www.sec.gov/Archives/edgar/data/1609809/000089924318024819/0000899243-18-024819-index.htm
2019-11-01Marcus ChapmanOfficerBuy12,000.0012,000.00https://www.sec.gov/Archives/edgar/data/1609809/000089924319028069/0000899243-19-028069-index.htm
2020-01-26Matthew R. HennOfficerBuy7,500.0012,000.00https://www.sec.gov/Archives/edgar/data/1609809/000089924320002211/0000899243-20-002211-index.htm
2019-01-28Eric D. ShaffOfficerSell4,378.005.7525,187.5112,842.00https://www.sec.gov/Archives/edgar/data/1609809/000089924319002138/0000899243-19-002138-index.htm
2018-08-15John G. AuninsOfficerSell14,279.007.57108,069.18132,369.00https://www.sec.gov/Archives/edgar/data/1609809/000089924318024819/0000899243-18-024819-index.htm
2018-05-15John G. AuninsOfficerSell14,279.008.08115,400.02146,648.00https://www.sec.gov/Archives/edgar/data/1609809/000089924318024819/0000899243-18-024819-index.htm
2019-01-26DAVID N COOKOfficerBuy7,500.00147,435.00https://www.sec.gov/Archives/edgar/data/1609809/000089924319002136/0000899243-19-002136-index.htm
2019-01-28Thomas DesRosierChief Legal Officer and EVPSell5,471.005.7531,477.9516,054.00https://www.sec.gov/Archives/edgar/data/1609809/000089924319002141/0000899243-19-002141-index.htm
2018-07-15John G. AuninsChief Technology Officer & EVPSell14,279.008.10115,725.58160,927.00https://www.sec.gov/Archives/edgar/data/1609809/000089924318020074/0000899243-18-020074-index.htm
2019-01-26Eric D. ShaffOfficerBuy12,000.0017,220.00https://www.sec.gov/Archives/edgar/data/1609809/000089924319002138/0000899243-19-002138-index.htm
2018-09-07Roger PomerantzPresident and CEOSell1,810.009.0016,291.27213,976.00https://www.sec.gov/Archives/edgar/data/1609809/000089924318024194/0000899243-18-024194-index.htm
2019-01-26Thomas DesRosierChief Legal Officer and EVPBuy15,000.0021,525.00https://www.sec.gov/Archives/edgar/data/1609809/000089924319002141/0000899243-19-002141-index.htm
2018-09-06Roger PomerantzPresident and CEOSell3,013.009.0427,235.41215,786.00https://www.sec.gov/Archives/edgar/data/1609809/000089924318023938/0000899243-18-023938-index.htm
2018-09-05Roger PomerantzPresident and CEOSell9,505.009.1286,714.12218,799.00https://www.sec.gov/Archives/edgar/data/1609809/000089924318023938/0000899243-18-023938-index.htm
2018-06-25Roger PomerantzPresident and CEOSell26,752.009.21246,503.63228,304.00https://www.sec.gov/Archives/edgar/data/1609809/000089924318018520/0000899243-18-018520-index.htm
2018-06-26Roger PomerantzPresident and CEOSell21,224.009.19195,133.46228,304.00https://www.sec.gov/Archives/edgar/data/1609809/000089924318018520/0000899243-18-018520-index.htm
2018-06-27Roger PomerantzPresident and CEOSell16,991.009.03153,408.34228,304.00https://www.sec.gov/Archives/edgar/data/1609809/000089924318018520/0000899243-18-018520-index.htm
2018-06-28Roger PomerantzPresident and CEOSell21,560.009.15197,375.33228,304.00https://www.sec.gov/Archives/edgar/data/1609809/000089924318018742/0000899243-18-018742-index.htm
2018-06-29Roger PomerantzPresident and CEOSell4,496.009.1040,915.40228,304.00https://www.sec.gov/Archives/edgar/data/1609809/000089924318018742/0000899243-18-018742-index.htm
2018-07-06Roger PomerantzPresident and CEOSell15,366.009.14140,506.70228,304.00https://www.sec.gov/Archives/edgar/data/1609809/000089924318019711/0000899243-18-019711-index.htm
2018-07-09Roger PomerantzPresident and CEOSell10,981.009.14100,350.97228,304.00https://www.sec.gov/Archives/edgar/data/1609809/000089924318019711/0000899243-18-019711-index.htm
2018-07-10Roger PomerantzPresident and CEOSell5,989.009.0554,207.64228,304.00https://www.sec.gov/Archives/edgar/data/1609809/000089924318019711/0000899243-18-019711-index.htm
2018-07-11Roger PomerantzPresident and CEOSell1,010.009.019,098.99228,304.00https://www.sec.gov/Archives/edgar/data/1609809/000089924318019814/0000899243-18-019814-index.htm
2018-07-11Roger PomerantzPresident and CEOBuy1,010.000.71717.10229,314.00https://www.sec.gov/Archives/edgar/data/1609809/000089924318019814/0000899243-18-019814-index.htm
2018-06-29Roger PomerantzPresident and CEOBuy4,496.000.713,192.16232,800.00https://www.sec.gov/Archives/edgar/data/1609809/000089924318018742/0000899243-18-018742-index.htm
2018-07-10Roger PomerantzPresident and CEOBuy5,989.000.714,252.19234,293.00https://www.sec.gov/Archives/edgar/data/1609809/000089924318019711/0000899243-18-019711-index.htm
2018-07-09Roger PomerantzPresident and CEOBuy10,981.000.717,796.51239,285.00https://www.sec.gov/Archives/edgar/data/1609809/000089924318019711/0000899243-18-019711-index.htm
2018-07-06Roger PomerantzPresident and CEOBuy15,366.000.7110,909.86243,670.00https://www.sec.gov/Archives/edgar/data/1609809/000089924318019711/0000899243-18-019711-index.htm
2018-06-27Roger PomerantzPresident and CEOBuy16,991.000.7112,063.61245,295.00https://www.sec.gov/Archives/edgar/data/1609809/000089924318018520/0000899243-18-018520-index.htm
2018-06-26Roger PomerantzPresident and CEOBuy21,224.000.7115,069.04249,528.00https://www.sec.gov/Archives/edgar/data/1609809/000089924318018520/0000899243-18-018520-index.htm
2018-06-28Roger PomerantzPresident and CEOBuy21,560.000.7115,307.60249,864.00https://www.sec.gov/Archives/edgar/data/1609809/000089924318018742/0000899243-18-018742-index.htm
2018-06-25Roger PomerantzPresident and CEOBuy16,288.000.7111,564.48255,056.00https://www.sec.gov/Archives/edgar/data/1609809/000089924318018520/0000899243-18-018520-index.htm
2020-01-26Eric D. ShaffCEO and PresidentBuy20,000.0032,842.00https://www.sec.gov/Archives/edgar/data/1609809/000089924320002213/0000899243-20-002213-index.htm
2020-01-26Thomas DesRosierChief Legal Officer and EVPBuy25,000.0041,054.00https://www.sec.gov/Archives/edgar/data/1609809/000089924320002212/0000899243-20-002212-index.htm
2019-06-18NOUBAR AFEYANDirectorBuy4,444,444.002.259,999,999.004,444,444.00https://www.sec.gov/Archives/edgar/data/1609809/000089924319017640/0000899243-19-017640-index.htm
2018-12-17John G. AuninsChief Technology Officer & EVPSell14,282.006.3991,313.4075,250.00https://www.sec.gov/Archives/edgar/data/1609809/000089924318031411/0000899243-18-031411-index.htm
2018-12-19John G. AuninsChief Technology Officer & EVPBuy10,000.0085,250.00https://www.sec.gov/Archives/edgar/data/1609809/000089924318031411/0000899243-18-031411-index.htm
2019-11-22Marcus ChapmanOfficerSell3,400.003.9113,296.728,600.00https://www.sec.gov/Archives/edgar/data/1609809/000089924319028069/0000899243-19-028069-index.htm
2018-11-15John G. AuninsOfficerSell14,279.008.26117,911.7089,532.00https://www.sec.gov/Archives/edgar/data/1609809/000089924318029310/0000899243-18-029310-index.htm
2019-01-26John G. AuninsChief Technology OfficerBuy7,500.0092,750.00https://www.sec.gov/Archives/edgar/data/1609809/000089924319002137/0000899243-19-002137-index.htm